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Abstract 
 
Objectives 
The UK & Ireland Implanters’ registry is a multicentre registry which reports on real-world 
experience with novel transcatheter heart valves. 
 
Background 
The 34 mm Evolut R transcatheter aortic valve is a self-expanding and fully recapturable 
transcatheter aortic valve, designed to treat patients with a large aortic annulus. 
 
Methods 
Between January 2017 and April 2018, clinical, procedural and 30-day outcome data were 
prospectively collected from all patients receiving the 34 mm Evolut R valve across 17 
participating centres in the United Kingdom and Ireland. The primary efficacy outcome was 
the Valve Academic Research Consortium-2(VARC-2)-defined endpoint of device success. 
The primary safety outcome was the VARC-2-defined composite endpoint of early safety at 
30 days. 
 
Results 
A total of 217 patients underwent attempted implant. Mean age was 79.5 ± 8.8 years and 
Society of Thoracic Surgeons Predicted Risk of Mortality Score 5.2 ± 3.4%. Iliofemoral 
access was used in 91.2% of patients. Device success was 79.7%. Mean gradient was 7.0 ± 
4.6 mm Hg and effective orifice area 2.0 ± 0.6 cm2. Paravalvular regurgitation was more than 
mild in 7.2%. A new permanent pacemaker was implanted in 15.7%. Early safety was 
demonstrated in 91.2%. At 30 days, all-cause mortality was 3.2%, stroke 3.7% and major 
vascular complication 2.3%. 
 
Conclusions 
Real-world experience of the 34 mm Evolut R transcatheter aortic valve demonstrated 
acceptable procedural success, safety, valve function and incidence of new permanent 
pacemaker implantation. 
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Introduction 
 
Transcatheter aortic valve replacement (TAVR) with a self-expanding prosthesis is a well-
established therapy for the treatment of patients with severe aortic stenosis who are at 
extreme, high and intermediate-risk for surgery (1-3). Until recently, patients with an aortic 
annulus diameter >29 mm were not treatable with a self-expanding prosthesis, and further, 
patients with an aortic annulus diameter >29.5 mm were not treatable with any commercially 
available transcatheter aortic valve (4). 
The 34 mm Evolut R transcatheter aortic valve (Medtronic, Minneapolis, Minnesota) 
is a second-generation transcatheter aortic valve which is designed to treat patients with an 
aortic annulus diameter between 26 and 30 mm. The key design changes from the first-
generation CoreValve have been described previously (5). In brief, the nitinol frame has been 
modified so that the inflow portion is wider and more cylindrical, providing more consistent 
radial force. The outflow portion is shorter and narrower, improving anatomical fit in highly 
angulated aortas. The porcine pericardial inflow skirt has been extended, with the aim of 
reducing paravalvular regurgitation. The valve is delivered using the 16-F equivalent EnVeo 
R delivery catheter system, which reduces the minimum transarterial access vessel diameter 
to 5.5 mm. The system may also be delivered through a 20-F introducer sheath. The nitinol 
delivery catheter capsule allows for resheathing and full recapture during deployment. 
 The UK & Ireland Implanters’ registry is a multicentre registry which reports on real-
world experience with novel transcatheter heart valves. Our group has previously reported on 
the procedural, clinical and 30-day outcome data of the 23, 26 and 29 mm Evolut R 
transcatheter aortic valves, which reflected our early experience with the Evolut R system 
between December 2013 and May 2016 (6). Here we describe our initial experience with the 
34 mm Evolut R valve. 
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Materials and Methods 
 
Between January 2017 and April 2018, clinical, procedural and 30-day outcome data were 
prospectively collected on all patients receiving the 34 mm Evolut R valve across 17 
participating centres in the United Kingdom and Ireland. 
The primary efficacy outcome was the Valve Academic Research Consortium-2 
(VARC-2)-defined composite endpoint of device success at 30 days (7). This composite 
endpoint requires the presence of all of the following (1) absence of procedural (30-day and 
index hospitalization) mortality, (2) correct positioning of a single prosthetic heart valve into 
the proper anatomical location, (3) no patient-prosthesis mismatch (body surface area indexed 
effective orifice area of >0.85 cm2/m2 or >0.70 cm2/m2 for patients with a body mass index 
30 kg/m2), (4) a mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s, and (5) no 
moderate or severe prosthetic valve regurgitation. 
The primary safety outcome was the VARC-2-defined composite endpoint of early 
safety at 30 days. Components of this endpoint are (1) all-cause mortality, (2) all stroke, (3) 
life-threatening bleeding, (4) acute kidney injury stage 2 or 3 (including renal replacement 
therapy), (5) coronary artery obstruction requiring intervention, (6) major vascular 
complication, and (7) valve-related dysfunction requiring a repeat procedure (balloon aortic 
valvuloplasty, TAVR or surgical aortic valve replacement). 
Secondary outcomes included 30-day valve hemodynamics, paravalvular 
regurgitation severity, new permanent pacemaker implantation and symptom status. 
 
Statistical analysis 
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Statistical analysis was performed with SPSS version 24.0 (IBM Corporation, Armonk, New 
York). Categorical variables are summarized as numbers and percentages. Continuous 
variables are presented as mean ± SD or median (interquartile range). Comparisons between 
continuous and categorical variables were evaluated with Student’s t-test and Fisher’s exact 
test, respectively, with a two-sided p value <0.05 considered statistically significant. 
 
Results 
 
Patient Characteristics 
A total of 217 patients underwent attempted implant. Baseline characteristics are listed in 
Table I. Patients were elderly (age 79.5 ± 8.8 years), largely male (95.4%) and at 
intermediate-risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality 5.2 ± 
3.4%). There was a high prevalence of frailty (18.9%). Although the majority of patients 
were treated for native tricuspid aortic stenosis, there was a relatively high prevalence of 
complex anatomy, including pure native aortic regurgitation (4 patients), failed bioprosthetic 
aortic valve replacement (1 patient), failed aortic root homograft (2 patients) and bicuspid 
aortic stenosis (12 patients). The mean aortic annulus diameter was 27.1 ± 1.7 mm (mean 
aortic annulus perimeter 86.4 ± 4.9 mm), the largest aortic annulus diameter was 31 mm 
(perimeter 103.0 mm) and 13 patients (6.0%) had an aortic annulus larger than the 
manufacturer recommendations. 
 
Procedural Characteristics 
Procedural characteristics are listed in Table II. Cases were mostly performed under local 
anaesthesia or conscious sedation (59.0%). Iliofemoral access predominated (91.2%) with 
subclavian access being the most common alternative access approach (7.4%). For 
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iliofemoral cases, the valve was typically delivered using the 16-F equivalent EnVeo R 
delivery catheter, without the need for a separate introducer sheath (89.9%). Pre-implant 
balloon valvuloplasty was performed in 52.1% of cases. The resheathing or recapture 
functionality was used in 27.2% of cases. Final implant depth was 5.6 ± 3.1 mm. Post-
implant balloon valvuloplasty was performed in 21.7% of cases. Median length of stay post-
procedure was 3 days (interquartile range 2 to 5 days). 
 
Device Success 
Overall device success was 79.7% (Table III). There were two cases where a transcatheter 
aortic valve could not be deployed. One iliofemoral case had to be terminated due to an 
inability to advance the delivery catheter through the iliac vessels. One valve could not be 
deployed in a stable position in an aortic root homograft and was fully recaptured. 
There were four cases which required a second prosthesis. In the first case the valve 
become invaginated after resheathing and would not re-expand. It was fully recaptured and a 
second 34 mm Evolut R prosthesis was placed without sequelae. In the second case (aortic 
annulus diameter 30.6 mm) the valve migrated on release to a depth of 15 mm and there was 
severe paravalvular regurgitation. While attempting to snare the prosthesis back into the 
aortic annulus, the valve embolized into the ascending aorta and a second 34 mm Evolut R 
valve was then deployed without sequelae. In the third case (aortic annulus diameter 25.1 
mm), the valve embolized into the ascending aorta upon device release and a second 34 mm 
Evolut R valve was deployed without complication. In the fourth case (aortic annulus 
diameter 28.5 mm) the valve migrated on release to a depth of 20 mm, which was associated 
with severe paravalvular regurgitation. Two additional 34 mm Evolut R prostheses were 
deployed, reducing paravalvular regurgitation to moderate. 
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There were an additional three cases of valve migration, all of which occurred 
immediately after final release (Table IV). There were no cases of coronary occlusion, 
annular rupture, ventricular perforation or need for sternotomy. 
 
Early Safety 
Early safety was demonstrated in 91.2%. (Table III). There were no immediate procedural 
mortalities, but seven patients (3.2%) died within 30 days of the procedure. Two patients died 
from bleeding (one from femoral access site vascular injury, one from complications of 
sternotomy for direct aortic approach). One patient died from spontaneous myocardial 
infarction four days post-procedure. There were four non-cardiac deaths. There were eight 
strokes (3.7%) and five major vascular complications (2.3%). 
Re-intervention was required in three patients. The first patient developed moderate 
paravalvular regurgitation, which was treated 14 days post procedure with a second 34 mm 
Evolut R valve, reducing severity to trivial. The second patient developed moderate 
paravalvular regurgitation, which was treated 63 days post procedure with balloon 
valvuloplasty using a 24 mm TRUE dilatation balloon (BARD Peripheral Vascular, Tempe, 
Arizona), reducing severity to mild. The third patient developed severe paravalvular 
regurgitation and was treated 103 days post procedure with an AMPLATZER Vascular Plug 
4 (Abbott Vascular, Santa Clara, California), reducing severity to moderate. 
 
Secondary Outcomes 
Echocardiographic follow-up was available for 207 patients. At 30 days, mean gradient was 
7.0 ± 4.6 mm Hg and effective orifice area 2.0 ± 0.6 cm2 (Figure 1). More than mild 
paravalvular regurgitation was present in 15 patients (7.2%) (Figure 2).  
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A new permanent pacemaker was implanted in 15.7% of patients without a 
pacemaker at baseline. 
Follow-up symptom status information was available for 108 patients. Symptom relief 
was observed, with 91 patients (84.3%) improving by at least one New York Heart 
Association functional class (Figure 3). 
 
Outcomes in Bicuspid Patients 
Twelves patients were treated for bicuspid aortic stenosis. One patient development moderate 
paravalvular regurgitation (8.3%) and two patients required permanent pacemaker 
implanation (22.9% of patients without a pacemaker at baseline). Early safety was 
demonstrated in all patients. 
 
Outcomes in Pure Aortic Regurgitation 
Four inoperable patients were treated for pure aortic regurgitation. Device annular sizing ratio 
was 28.3 ± 2.6%. There were no cases of moderate paravalvular regurgitation and two 
patients (50.0%) required permanent pacemaker implantation. There was one case of valve 
migration as has previously been discussed. Early safety was demonstrated in all patients. 
 
Risk Factors for Complications 
Pre-existing right bundle branch block was associated with a significantly higher risk of new 
permanent pacemaker (62.5% vs. 13.5%, p = 0.003). Implant depth was significantly lower in 
patient requiring a new permanent pacemaker (8.9 ± 3.7 vs. 4.8 ± 2.2 mm, p <0.001) and 
further, a deep implant (>5 mm) was associated with a significantly higher risk of new 
permanent pacemaker (35.1 vs. 10.6%, p <0.001). 
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 Device annular sizing ratio was significantly lower in patients who developed more 
than mild paravalvular regurgitation (19.8 ± 7.3 vs. 26.0 ± 7.9%, p = 0.04). 
 
Comparison to the 23, 26 and 29 mm Valve Sizes 
When compared to our previous experience of the smaller valve sizes, patients in the 34 mm 
registry had broadly similar baseline characteristics, but with some important differences 
(Supplementary Table I). The 34 mm group had a higher proportion of men and a higher 
prevalence of pre-existing permanent pacemaker or defibrillator. Fewer valve-in-valve 
procedures were undertaken with the 34 mm valve size. 
Procedural differences were noted between the two cohorts (Supplementary Table II). 
The 34 mm valve procedures, which were undertaken in a more contemporary time period, 
were more frequently performed under local anesthesia or conscious sedation. The larger 
valve size saw more frequent usage of the EnVeo R delivery catheter without an introducer 
sheath. Both pre-implant balloon valvuloplasty and use of the EnVeo R delivery system’s 
resheathing and recapture function were more common with the 34 mm valve size. 
 Device success, early safety, more than mild paravalvular regurgitation and new 
permanent pacemaker implantation were all similar between the two cohorts (Supplementary 
Table III). Mean aortic valve gradient was lower (7.0 ± 4.6 vs. 8.3 ± 6.0 mm Hg, p = 0.02) 
and effective orifice area was larger (2.0 ± 0.6 vs. 1.7 ± 0.5 cm2, p <0.001) with the 34 mm 
valve size. 
 
Discussion 
 
We describe here the clinical, procedural and 30-day outcome data of a large cohort of 
consecutive, real-world patients treated with the 34 mm Evolut R transcatheter aortic valve. 
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Procedural indications were broad, and we demonstrated successful implantations in 
bioprosthetic surgical valves, aortic root homografts, pure native aortic regurgitation and 
bicuspid aortic valve morphology. 
Valve implantation demonstrated a favourable safety profile (all-cause mortality 
3.2%, stroke 3.7%, life-threatening bleeding 0.9% and major vascular complication 2.3%). 
Device success (79.7%) was similar to our experience with the smaller valve sizes 
(72.3%) and outcomes reported in the Evolut R CE Mark clinical trial (78.6%) (8). Patient-
prosthesis mismatch (7.8%) was the largest driver for an unsuccessful procedure, the 
incidence of which was lower than our experience with the smaller valve sizes (16.3%) and 
outcomes reported in the Evolut R CE Mark (16.4%) and Evolut R U.S. (26.8%) clinical 
studies (9). 
Valve hemodynamics were excellent with a low mean aortic valve gradient (7.0 ± 4.6 
mm Hg) and large effective orifice area (2.0 ± 0.6 cm2). Only three patients had a mean aortic 
valve gradient 20 mmHg or peak velocity 3 m/sec. 
Incidence of more than mild paravalvular regurgitation at 30-days (7.2%) was similar 
to our experience with the smaller valve sizes (7.8%) and outcomes reported in both the 
Evolut R CE Mark (6.7%) and Evolut R U.S. (5.3%) clinical studies.(8,9) These findings 
represent a definite improvement on the outcomes seen with the first-generation CoreValve in 
the ADVANCE clinical study (15.0%) (10). However, incidence of more than mild 
paravalvular regurgitation was not as low as has been recently reported in the Evolut R 
FORWARD clinical study (1.9%), Evolut R 34 mm U.S. clinical study (1.7%), Evolut PRO 
U.S. clinical study (0.0%) and other 34 mm Evolut R registry data (0.0-5.0%) (11-16). The 
average implant depth in our study (5.6 ± 3.1 mm) was outside the manufacturer 
recommendations (3-5 mm), which may explain the higher incidence of more than mild 
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paravalvular regurgitation that we have reported. A 34 mm Evolut PRO valve is currently in 
development, which should reduce this complication. 
Incidence of new permanent pacemaker insertion (15.7%) was similar to our 
experience of the smaller Evolut R prosthesis sizes. However, pre-existing permanent 
pacemaker was more common in patients treated with the 34 mm prosthesis, perhaps 
reflective of an increased tendency for operators to implant prophylactic pacemakers. 
The resheating and recapture ability was frequently used to optimise positioning 
(27.2%) and in two cases was employed to completely remove the transcatheter aortic valve 
from the patient. Usage of these features was more common than with our previous 
experience of the smaller valve sizes, which probably reflects greater operator experience 
using this technology, but may also be indicative of the difficulties in placing transcatheter 
aortic valves in large anatomy, due to an increased prevalence of excessive aortic root 
angulation. 
The 16-F equivalent EnVeo R delivery catheter system is larger than the 14-F 
equivalent system used for the 23 to 29 mm Evolut R valves. However, as iliofemoral vessels 
were larger in this cohort, iliofemoral access rates were similar and major vascular 
complications remained low (2.3%). More 34 mm procedures were performed without an 
introducer sheath, likely reflecting greater operator familiarity using the in-line sheath feature 
of the EnVeo R delivery system. 
Valve embolization occurred in 2 patients, both whom had aortic annulus dimensions 
outside the manufacturer recommended sizing algorithm. A second 34 mm Evolut R 
prosthesis was successfully implanted in both cases. 
Pre-existing right bundle branch block and a low implant depth are both well-
established risk factor for new permanent pacemaker implantation after TAVR (17). We 
confirmed that these clinical and procedural characteristics were both associated with new 
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permanent pacemaker implantation after TAVR with the 34mm Evolut R valve. Device 
annular sizing ratio was associated with the development of more than mild paravalvular 
regurgitation, as has previously been described (9). 
The incidence of moderate paravalvular regurgitation reported in this study (7.2%) 
was similar to a recent series of large annuli patients treated with the SAPIEN 3 valve (6.9%) 
(Edwards Lifesciences, Irvine, California), but incidence of permanent pacemaker was higher 
with the the self-expanding prosthesis (15.7% vs 6.3%) (18). 
 
Limitations 
 
This study should be interpreted within the inherent constraints of a registry. All clinical 
outcomes were site reported. There was no usage of a core laboratory for assessing 
echocardiographic outcomes. Echocardiographic and clinical follow-up information was not 
available for all patients. Further work is needed to establish long-term prosthesis durability. 
However, this study has considerable strengths, specifically the prospective, 
consecutive data collection on real-world, unselected patients, that reflect day-to-day clinical 
practice. 
 
Conclusion 
 
In this study we have described our initial experience of a large, self-expanding and fully 
recapturable transcatheter aortic valve. Procedural success, safety, valve function and 
incidence of new permanent pacemaker implantation were all acceptable and similar to 
previous studies of the Evolut R prosthesis. 
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Figure Titles and Descriptive Legends 
 
Figure 1. Aortic Valve Hemodynamics. 
Error bars represent 1 SD. 
 
Figure 2. Aortic/Paravalvular Regurgitation. 
 
Figure 3. Symptom Status. 
NYHA = New York Heart Association. 
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